Electrical Inhibition of Human Preterm Contractions

December 1, 2024 updated by: e-Bio Corp

Electrical Inhibition (EI): A Preliminary Study to Prevent the Uterine Contractions of Human Preterm Labor and Preterm Birth

The purpose of this study is to explore a new method to stop preterm uterine contractions using an electrical device. The device, an "electrical pacemaker for the uterus," has been approved by the Food and Drug Administration (FDA) for clinical research in pregnant women. The purpose of this study is to evaluate the feasibility and safety of the device. The investigators hypothesize that human preterm uterine contractions can be safely and objectively inhibited with a weak electrical current provided by an electrical inhibition (EI)/uterine pacemaker device, and that this effect relates to the timing and length of EI exposure.

Study Overview

Detailed Description

The purpose of this study is to determine the effectiveness of a new method of preventing the human preterm uterine contractions of labor during electrical monitoring. The objective is to test a method for the inhibition of human preterm uterine contractions with an electrical pacemaker, electrical inhibition (EI). The study will investigate EI associated changes in preterm uterine contraction frequency as monitored by objective uterine tocodynamometry and adjunct electromyography (EMG) and electrohysterogram (EHG). The endpoint is the statistically significant EI induced decrease in the gold standard tocodynamometric monitored preterm uterine contraction frequency. The adjunct EMG and EHG monitoring provides valuable adjunct data about the electrical activity of the preterm uterine contractions and the effect of EI on this activity.

The investigators hypothesize that human preterm uterine contractions can be safely and objectively inhibited with a weak electrical current provided by an electrical inhibition (EI)/uterine pacemaker device. This effect can be assessed by the use of a non-invasive tocodynamometer. It has been previously been shown that the frequency of contractions during preterm labor can be lowered by EI applied by the use of an intravaginal catheter carrying electrodes similar to a cardiac pacemaker (Karsdon et al). The investigators hypothesize that this effect relates to the timing and length of EI exposure.

Study Type

Interventional

Enrollment (Estimated)

110

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Florida
      • Gainesville, Florida, United States, 32610
        • University of Florida

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 50 years (Adult)

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

  • Wong-Baker pain score ≤ 6
  • Pregnancy Depression Scale score < 16
  • Informed consent form signed and dated by patient
  • Be willing and able to comply with study requirements
  • Be between 18-50 years of age
  • Be between 23 to 36 5/7 weeks pregnant with a singleton gestation
  • Cervical dilation of ≤ 6 cm
  • A normal spontaneous vaginal delivery (NSVD) expected
  • Suspected to have preterm labor, as defined by the American College of Obstetricians and Gynecologists and the American Academy of Pediatrics, as follows.78

    • Persistent uterine contractions (4 every 20 minutes, or 8 every 60 minutes)
    • And any one or more of the following:
    • Documented cervical change
    • 1 cm cervical dilatation and progressing

      -> 80% cervical effacement

    • Be admitted to the maternity unit with the diagnosis of preterm labor or preterm contractions

Exclusion Criteria:

  • Severe preeclampsia
  • Severe abruption placenta
  • Abnormal placentation (i.e. placenta previa)
  • Rupture of amniotic membranes
  • Active preterm labor with cervical dilation > 6 cm
  • Exposed amniotic membranes
  • Vaginal bleeding > 10 cc
  • Frank chorioamnionitis
  • Fetal death
  • Fetal anomaly incompatible with life
  • Severe fetal growth restriction (EFW < 5%)
  • Uterine anomalies (i.e. bicornuate uterus, uterine didelphys)
  • Mature fetal lung studies
  • Maternal cardiac arrhythmias
  • HIV, Hepatitis C, Hepatitis B
  • History of herpes simplex virus (HSV)
  • A permanent cardiac pacemaker
  • A fetal cardiac arrhythmia
  • Contraindication for tocolysis e.g. premature rupture of the amniotic membranes allowing for ascending intrauterine infection with group B streptococcus or GBS (beta hemolytic streptococcus, S. agalactiae) or other micro-organisms.
  • IV or po narcotic pain medication < 12 hours prior to admission (regional anesthesia, long acting oral maintenance opiates i.e. methadone, Suboxone, Subutex not included in exclusion criteria)

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Non-Randomized
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: 60 Minute Study
After a 20-minute pre-intervention control period the electrical inhibition will be used intermittently, only when there is monitored contraction, during the 20-minute intervention study period. At the end of the intervention period there will be a 20-minute post-intervention control period. The FHR patterns, tocogram, EMG and EHG, and fECG recordings will be compared to before and after the use of the electrical uterine pacemaker device.
The catheter is placed under ultrasound guidance into the posterior vaginal fornix next to the external cervical os. The electrode connectors are attached to the EI device. Activating the EI device involves: 1) turning the current pulse duration rotary dial clockwise to the desired setting; this is an important setting and should be set at 20ms; 2) turning the current frequency rotary dial clockwise to the desired setting; 3) turn on the EI device on with the on/off toggle switch; 4) SLOWLY turning the current strength rotary dial clockwise to the desired setting, at this time the red light should be flashing. Usually 5-10mA of current is sufficient, but 20 mA is a maximum. Based on the tocometer recordings the least amount of EI current is given to inhibit the uterine contractions.
Experimental: 80 Minute Study
After a 20-minute pre-intervention control period the electrical inhibition will be used intermittently, only when there is monitored contraction, during the 40-minute intervention study period. At the end of the intervention period there will be a 20-minute post-intervention control period. The FHR patterns, tocogram, EMG and EHG, and fECG recordings will be compared to before and after the use of the electrical uterine pacemaker device.
The catheter is placed under ultrasound guidance into the posterior vaginal fornix next to the external cervical os. The electrode connectors are attached to the EI device. Activating the EI device involves: 1) turning the current pulse duration rotary dial clockwise to the desired setting; this is an important setting and should be set at 20ms; 2) turning the current frequency rotary dial clockwise to the desired setting; 3) turn on the EI device on with the on/off toggle switch; 4) SLOWLY turning the current strength rotary dial clockwise to the desired setting, at this time the red light should be flashing. Usually 5-10mA of current is sufficient, but 20 mA is a maximum. Based on the tocometer recordings the least amount of EI current is given to inhibit the uterine contractions.
Experimental: 120 Minute Study
After a 20-minute pre-intervention control period the electrical inhibition will be used intermittently, only when there is monitored contraction, during the 80-minute intervention study period. At the end of the intervention period there will be a 20-minute post-intervention control period. The FHR patterns, tocogram, EMG and EHG, and fECG recordings will be compared to before and after the use of the electrical uterine pacemaker device.
The catheter is placed under ultrasound guidance into the posterior vaginal fornix next to the external cervical os. The electrode connectors are attached to the EI device. Activating the EI device involves: 1) turning the current pulse duration rotary dial clockwise to the desired setting; this is an important setting and should be set at 20ms; 2) turning the current frequency rotary dial clockwise to the desired setting; 3) turn on the EI device on with the on/off toggle switch; 4) SLOWLY turning the current strength rotary dial clockwise to the desired setting, at this time the red light should be flashing. Usually 5-10mA of current is sufficient, but 20 mA is a maximum. Based on the tocometer recordings the least amount of EI current is given to inhibit the uterine contractions.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Uterine contraction frequency during labor as measured by external uterine tocodynamometric monitoring
Time Frame: Change from 20, 40, and 80 minutes
Change from 20, 40, and 80 minutes

Secondary Outcome Measures

Outcome Measure
Time Frame
FHR pattern as measured by the maternal-fetal monitor
Time Frame: Change from 60 and 120 minutes
Change from 60 and 120 minutes
EMG monitoring as measured by LaborView Device
Time Frame: Change from 60 and 120 minutes
Change from 60 and 120 minutes
EHG monitoring as measured by LaborView Device
Time Frame: Change from 60 and 120 minutes
Change from 60 and 120 minutes
fECG monitoring as measured by LaborView Device
Time Frame: Change from 60 and 120 minutes
Change from 60 and 120 minutes
Maternal pain medication administration
Time Frame: Before and after use of electrical uterine pacemaker, assessed up to 120 minutes
Before and after use of electrical uterine pacemaker, assessed up to 120 minutes
Maternal heart rate
Time Frame: Change from 60 and 120 minutes
Change from 60 and 120 minutes

Other Outcome Measures

Outcome Measure
Time Frame
Adverse events
Time Frame: Before and after use of electrical uterine pacemaker, assessed up to 120 minutes
Before and after use of electrical uterine pacemaker, assessed up to 120 minutes

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Investigators

  • Study Chair: Jeffrey Karsdon, MD, New York University Lagone Medical Center
  • Principal Investigator: John Smulian, MD, University of Florida

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

March 1, 2017

Primary Completion (Estimated)

January 21, 2026

Study Completion (Estimated)

January 21, 2026

Study Registration Dates

First Submitted

December 2, 2016

First Submitted That Met QC Criteria

December 5, 2016

First Posted (Estimated)

December 6, 2016

Study Record Updates

Last Update Posted (Actual)

December 4, 2024

Last Update Submitted That Met QC Criteria

December 1, 2024

Last Verified

December 1, 2024

More Information

Terms related to this study

Other Study ID Numbers

  • IRB201601699 - A
  • OCR26522 (Other Identifier: UF OnCore)
  • E-BIO CORP (Other Identifier: PRO00038898)

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

Yes

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Preterm Labor

Clinical Trials on Electrical Uterine Pacemaker

Subscribe